XFOR · XBRL financial data

X4 Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XFOR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue	—	—	—	0	2,600	6,500
Revenue from contracts with customers	3,000	0	0	0	2,557	35,113
Cost of revenue	—	—	0	0	797	5,757
Research and development	41,932	50,647	61,058	72,017	81,643	72,723
General and administrative	20,942	24,702	27,020	35,505	61,518	43,516
Total operating expenses	62,874	85,107	87,569	107,522	—	—
Operating income (loss)	(59,874)	(85,107)	(87,569)	(107,522)	(36,401)	(86,883)
Interest income	273	10	219	4,582	5,769	4,576
Interest expense	2,688	3,642	3,993	5,777	8,768	8,876
Other income (expense)	905	426	(4,197)	554	332	(753)
Income tax expense (benefit)	148	17	28	78	310	41
Net income (loss)	(62,131)	(88,696)	(93,867)	(101,167)	(37,450)	(79,199)
Earnings per share, basic‡ USD per share	(92.79)	(119.82)	(45.65)	(17.12)	(5.71)	(1.87)
Earnings per share, diluted‡ USD per share	(92.79)	(119.82)	(45.65)	(17.12)	(5.71)	(1.87)
Weighted average shares, basic‡ thousands of shares	669	857	2,115	5,921	6,695	42,293
Weighted average shares, diluted‡ thousands of shares	669	857	2,115	5,921	6,695	42,293

‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2025); filings made before it reported them unadjusted.
† Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XFOR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	78,708	81,787	121,718	99,216	55,699	217,049
Accounts receivable	—	—	—	0	1,070	573
Inventory	—	—	—	0	2,817	—
Prepaid and other current assets	3,682	5,344	5,807	7,298	5,588	3,527
Total current assets	83,307	87,878	128,677	122,076	112,175	261,577
Property and equipment, net	1,237	1,514	1,104	745	776	182
Right-of-use asset	7,960	8,710	7,229	5,650	4,065	1,409
Goodwill	27,109	17,351	17,351	17,351	17,351	17,351
Total assets	122,871	117,176	155,586	147,258	146,447	290,461
Accounts payable	3,144	4,283	7,777	8,947	8,621	5,696
Accrued liabilities	8,018	7,870	12,034	12,816	23,005	18,603
Current portion of long-term debt	0	795	1,315	0	—	—
Total current liabilities	11,948	14,023	22,324	22,862	32,877	25,757
Long-term debt	33,178	33,139	32,304	54,570	—	—
Lease liability, non-current	4,484	4,776	3,603	2,612	1,410	0
Total liabilities	50,072	52,764	81,535	96,159	124,298	104,171
Accumulated deficit	(194,175)	(282,871)	(376,738)	(477,905)	(515,355)	(594,554)
Total stockholders' equity	72,799	64,412	74,051	51,099	22,149	186,290
Total liabilities and equity	122,871	117,176	155,586	147,258	146,447	290,461
Common shares outstanding (cover page)‡ thousands of shares	579	1,026	4,070	5,592	5,783	90,920

‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2025); filings made before it reported them unadjusted.
† Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (XFOR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(62,131)	(88,696)	(93,867)	(101,167)	(37,450)	(79,199)
Stock-based compensation	5,428	6,180	5,199	8,687	8,204	4,298
Depreciation and amortization	351	499	513	419	796	1,277
Net cash from operating activities	(58,818)	(70,905)	(77,102)	(96,512)	(130,901)	(85,618)
Purchases of property and equipment	—	—	103	60	326	—
Net cash from investing activities	(1,362)	(615)	(103)	(14,883)	66,990	8,154
Proceeds from issuing common stock	—	—	—	59,999	0	238,530
Share repurchases	0	2,000	0	0	—	—
Repayments of long-term debt	0	0	795	2,064	0	0
Net cash from financing activities	12,394	74,245	117,230	88,516	20,294	238,628
Net change in cash	(47,384)	2,406	39,920	(22,780)	(43,773)	161,377

† Share count changed about 4x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.